OPEN END TURBO OPTIONSSCHEIN - JAZZ PHARMACEUTICALS Share Price

Certificat

DE000JQ3USC0

Real-time Bid/Ask 12:55:44 06/06/2024 BST
13.59 EUR / 13.69 EUR -0.94% Intraday chart for OPEN END TURBO OPTIONSSCHEIN - JAZZ PHARMACEUTICALS
Current month-1.43%
1 month+1.03%
Date Price Change
06/06/24 13.6 -1.23%
05/06/24 13.77 -0.65%
04/06/24 13.86 -0.14%
03/06/24 13.88 -0.64%
31/05/24 13.97 -1.27%

Delayed Quote Börse Stuttgart

Last update June 06, 2024 at 11:24 am

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellPUT
Underlying JAZZ PHARMACEUTICALS PLC
Issuer J.P. Morgan
WKN JQ3USC
ISINDE000JQ3USC0
Date issued 27/07/2022
Strike 255.4 $
Maturity Unlimited
Parity 10 : 1
Emission price 9.17
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 14.15
Lowest since issue 8.66
Spread 0.1
Spread %0.73%

Company Profile

Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).
Sector
-
More about the company

Ratings for Jazz Pharmaceuticals plc

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Jazz Pharmaceuticals plc

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
106.6 USD
Average target price
180.3 USD
Spread / Average Target
+69.13%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW